Lannett Co. Inc. | Balance Sheet

Fiscal year is July-June. All values USD Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
146
214
239
145
99
Total Accounts Receivable
61
91
212
204
253
Inventories
45
46
115
123
142
Other Current Assets
13
19
47
52
34
Total Current Assets
266
371
613
524
527
Net Property, Plant & Equipment
62
95
217
243
233
Intangible Assets
1
29
909
793
764
Other Assets
-
2
14
19
29
Total Assets
343
509
1,764
1,603
1,575
ST Debt & Current Portion LT Debt
-
-
178
60
67
Accounts Payable
21
19
35
45
57
Income Tax Payable
5
2
1
-
-
Other Current Liabilities
21
23
93
87
77
Total Current Liabilities
47
44
307
192
201
Long-Term Debt
1
1
884
844
772
Deferred Taxes
14
12
12
24
22
Other Liabilities
-
-
19
6
3
Total Liabilities
48
45
1,210
1,042
976
Common Equity (Total)
294
463
554
561
599
Total Shareholders' Equity
294
463
554
561
599
Total Equity
295
464
554
561
599
Liabilities & Shareholders' Equity
343
509
1,764
1,603
1,575
Accumulated Minority Interest
-
-
-
-
-

About Lannett Co.

View Profile
Address
9000 State Road
Philadelphia Pennsylvania 19136
United States
Employees -
Website http://www.lannett.com
Updated 07/08/2019
Lannett Co., Inc. engages in the development, manufacture, market, and distribution of generic pharmaceutical products. Its products include aqueous vitamin D 4; escltalopram oxalate; renitidine syrup; danazol; primidone; and isonlazid. The company was founded in 1942 and is headquartered in Philadelphia, PA.